Clinical Advisor

High Dose Spinraza Receives FDA Approval for Spinal Muscular Atrophy

This high dose nusinersen regimen for spinal muscular atrophy includes 50 mg loading doses and 28mg maintenance doses.
Zacks Investment Research on MSN

Biogen secures FDA nod for higher dose of SMA drug Spinraza

Shares of Biogen BIIB rose 2% on Monday after the company announced that the FDA approved a higher dose of its blockbuster ...
PharmTech

What the FDA’s High-Dose Nusinersen Approval Means for Drug Development

The FDA approved a high-dose nusinersen regimen for spinal muscular atrophy, offering pharma teams key insights into dose ...
Becker's Hospital Review

FDA approves higher-dose treatment for muscle disease

The FDA has approved a higher-dose regimen of Spinraza for spinal muscular atrophy, providing a new treatment option for patients. The regimen includes 50 milligram per 5 milliliter and 28 milligram ...
Nasdaq

Biogen Inc. Announces FDA and EMA Acceptance of Higher Dose Regimen for Nusinersen in Spinal Muscular Atrophy

Biogen Inc. announced that the FDA has accepted and the EMA has validated its supplemental New Drug Application for a higher dose regimen of nusinersen, intended for treating spinal muscular atrophy ...